ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年06月24日 08時00分
Source:
Eisai
エーザイ、新株予約権証券の発行登録書の提出について
東京, 2019年06月24日 - (JCN Newswire) - 当社は、本日、「当社企業価値・株主共同の利益の確保に関する対応方針」(以下、本対応方針) に基づき、新株予約権証券の発行登録書を関東財務局に提出しました。本発行登録書の概要は下記の通りです。なお、本件は2018年6月20日に提出した発行登録書の期間(2018年7月1日から2019年6月30日)終了に対応するものです。
1.募集有価証券の種類:新株予約権証券
2.発行予定期間:発行登録の効力発生予定日から1年を経過する日まで (2019年7月1日から2020年6月30日)
3.募集方法:株主割当
4.発行予定額:8億円
(上記は、新株予約権証券の発行価額の総額(無償)に新株予約権の行使に際して払い込むべき金額の合計額を合算した金額)
2019年6月20日に開催した取締役会において、社外取締役独立委員会より本対応方針を継続する旨の提案がなされ、審議の結果、提案通りに決議しました。
本発行登録は機動的な株主割当による新株予約権発行を可能とするものです。
本対応方針の内容は、こちらをご参照ください。
(
https://www.eisai.co.jp/news/2019/pdf/news201944pdf.pdf
)
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026
Feb 22, 2025 04:50 JST
Honda Receives Highest Ranking of 3 Stars as Part of FIA Road Safety Index, Tool for Organizations and Companies to Measure Their Road Safety Footprint
Feb 21, 2025 19:40 JST
Honda Partners with United Nations Road Safety Fund (UNRSF) to Work Toward Reduction of Fatalities from Traffic Collisions
Feb 21, 2025 19:11 JST
Mitsubishi Logistics Corporation, Mitsubishi Corporation, and Yourstand Inc. Advancing Completely CO2-Free Electrification of Pharmaceutical Transportation
Feb 21, 2025 15:01 JST
NEC Innovation Challenge awards Canada's Prevu3D Inc. with the NEC Award and NOFF Award
Feb 21, 2025 14:39 JST
NEC Develops Near Real-time RIC for High Performance 5G vRAN
Feb 21, 2025 12:00 JST
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 20, 2025 13:29 JST
NEC X & Carbide Ventures Partner To Rapidly Accelerate Early-Stage Startups
Feb 19, 2025 20:16 JST
Mitsubishi Power Advances Bahrain's Industrial Growth with Completion of Alba's Power Station 5 Block 4 Combined Cycle Power Plant Project
Feb 19, 2025 16:54 JST
Honda Reveals Specification for its Next-generation Fuel Cell Module
Feb 19, 2025 11:07 JST
NEC Orchestrating Future Fund invests in Aetion, a U.S.-based provider of healthcare analytics platforms
Feb 19, 2025 09:08 JST
Osaka Gas and MHI Launch CO2NNEX Digital Platform for Management and Transfer of Clean Gas Certificates for e-Methane, for Use during Expo 2025
Feb 18, 2025 13:18 JST
TOYOTA GAZOO Racing starts WEC season with Qatar challenge
Feb 17, 2025 18:45 JST
FLAT OUT IN TOKYO "Red Bull Showrun x Powered by Honda" April 2 (Wed)
Feb 17, 2025 16:21 JST
Thrilling TOYOTA GAZOO Racing one-two on Swedish snow
Feb 17, 2025 14:23 JST
Launch of Joint Demonstration Experiment of Remote Provision of GPU Computing Power
Feb 17, 2025 14:10 JST
Mazda to Strengthen Production and Sales Systems in Thailand
Feb 14, 2025 17:04 JST
Toyota Develops New Fuel Cell System
Feb 14, 2025 15:27 JST
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 14, 2025 12:09 JST
Nissan, Honda and Mitsubishi Motors terminate MOU regarding consideration of tripartite collaboration
Feb 13, 2025 16:20 JST
More Latest Release >>
Related Release
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2025 1:29:00 PM JST
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
2/14/2025 12:09:00 PM JST
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
2/3/2025 5:23:00 PM JST
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/28/2025 9:46:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
1/22/2025 5:18:00 PM JST
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/15/2025 10:03:00 AM JST
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
1/7/2025 9:14:00 AM JST
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
12/23/2024 5:22:00 PM JST
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
12/11/2024 2:45:00 PM JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
12/5/2024 11:22:00 AM JST
More Press release >>